Updates are available Correction dated 2025-01-07
Click to view Correction: https://doi.org/10.1038/s41572-025-00592-8
-
Authors
Hendriks, Lizza E. L. https://orcid.org/0000-0002-3521-2535
Remon, Jordi
Faivre-Finn, Corinne
Garassino, Marina C.
Heymach, John V. https://orcid.org/0000-0001-9068-8942
Kerr, Keith M.
Tan, Daniel S. W. https://orcid.org/0000-0002-6514-6786
Veronesi, Giulia
Reck, Martin https://orcid.org/0000-0002-5348-4462
- License Information
-
More Information
Article History
Accepted: 19 August 2024
First Online: 26 September 2024
Change Date: 7 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-025-00592-8
Competing interests
: L.E.L.H reports grants and/or research support (all paid to institution) from Roche, Boehringer Ingelheim, AstraZeneca, Takeda, Merck, Pfizer, Novartis and Gilead; is on the advisory boards (all to institution) of Amgen, Boehringer Ingelheim, Lilly, Novartis, Pfizer, Takeda, Merck, Janssen, Merck Sharp & Dohme (MSD), AnHeart Therapeutics, Bayer, Daiichi, Pierre Fabre, BMS, AbbVie, AstraZeneca and Summit Therapeutics; was a speaker on educational seminars or webinars for AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GlaxoSmithKline (GSK), Sanofi and Pfizer (all paid to the institution) and Medtalks, Benecke, VJOncology and Medimix (personal payment); performed local PI pharma studies (all to institution) with AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, AbbVie, Gilead, MSD, Pfizer, Amgen and Boehringer Ingelheim; and was on member guideline committees in a personal capacity for Dutch guidelines on NSCLC, brain metastases and leptomeningeal metastases (personal payment), and ESMO guidelines on NSCLC and small-cell lung cancer (unpaid). J.R. reports investigator support from MSD; honoraria for advisory board (paid to institution) from AstraZeneca, Edimark, Janssen; study support (paid to institution) from Merck; and travel support from OSE-Immunotherapeutics and MSD. C.F.-F. reports research funding from AstraZeneca (to institution) and honoraria for consultancy of AstraZeneca and MSD (paid to institution). M.C.G. reports personal honoraria for consultancy and speaker appointments from AstraZeneca, Abion, MSD International GmbH, Bayer, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Incyte, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati, Daiichi–Sankyo, Regeneron, Merck, Blueprint, Jansen, Sanofi, AbbVie, BeiGenius, Oncohost, Medscape, Gilead and Io Biotech. M.C.G. reports honoraria paid to the institution for consultancy and speaking commitments from Eli Lilly, MSD, Pfizer (MISP), AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, GSK and Spectrum Pharmaceuticals. J.V.H. reports honoraria for advisory committees from AbbVie, AnHeart Therapeutics, ArriVent Biopharma, AstraZeneca, BioCurity Pharmaceuticals, BioNTech AG, Blueprint Medicines, BI, BMS, Chugai Pharmaceutical, Curio Science, DAVA Oncology, Eli Lily & Co., EMD Serono, Genentech, GSK, IDEOlogy Health, Immunocore, InterVenn Biosciences, Janssen Biotech, Janssen Pharmaceuticals, Mirati Therapeutics, Moffitt Cancer Center, Nexus Health Systems, Novartis Pharmaceuticals, OncoCyte, RefleXion, Regeneron Pharmaceuticals, Roche, Sandoz Pharmaceutical, Sanofi, Spectrum Pharmaceuticals, Takeda and uniQure; research support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb (BMS) and Takeda; and honoraria for licensing and royalties from Spectrum. K.M.K. reports honoraria for speaker commitments from AbbVie, AstraZeneca, Amgen, Boehringer Ingelheim, BMS, Janssen, Merck Serono, MSD, Mirati, Novartis, Pfizer, Roche, Sanofi, Ventana, Medscape, Prime Oncology, PeerVoice and PER; and honoraria for consultancy from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daichi Sankyo, Janssen, Merck Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and Ventana. D.S.W.T. reports honoraria for consultancy from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, DKSH, GSK, Merck, Novartis, Pfizer, Roche and Takeda; research support from ACM Biolabs, Amgen, AstraZeneca and Pfizer; and stock options from Oncoshot, C2i and Genomics. G.V. reports no competing interests. M.R. reports honoraria for speaking commitments and consultancy from Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, Daiichi–Sankyo, GSK, Lilly, Merck, MSD, Mirati, Novartis, Pfizer, Regeneron and Roche; and research support from Boehringer Ingelheim and BMS.
